- MTB-CAMELIA (ANRS 12278)
The CAMELIA trial (ANRS 1295) showed a markedly improved survival when ART was initiated at 2 weeks compared to 8 weeks after TB treatment onset in HIV-infected adults with CD4 ≤ 200/mm3 (Blanc et al., NEJM, 2011). The main cause of mortality was TB (Marcy et al., CID, 2014) and TB-associated IRIS was very common (Laureillard et al., AIDS, 2013). In this CAMELIA nested-study, we want to investigate the association of Mycobacterium tuberculosis (Mtb) genotypes with the severity of TB and with different outcomes such as mortality and occurrence of TB-IRIS. All the Mtb isolates are genetically characterized and will be analyzed with the clinical data.
- STATIS (ANRS 12290):
A multicentre (Cambodia, Côte d’Ivoire, Uganda, Vietnam) randomized clinical trial to compare the 24-week risk of death and occurrence of invasive bacterial infection between 2 strategies in HIV-1 infected adults who ART with CD4 <100/mm3: (i) continuous extensive TB screening during follow-up each time the patient present with symptoms, versus. (ii) systematic empirical TB treatment started 2 weeks before ART initiation.
- REFLATE TB-2 (ANRS 12300):
A multicentre (Brazil, Côte d’Ivoire, France, Mozambic, Vietnam) randomized clinical trial to assess the non-inferiority of Raltegravir compared with Efavirenz, both in combination with Lamivudine and Tenofovir, in ART-naïve HIV-1-infected patients receiving rifampin for TB treatment.
FIBRHIVIET-ANRS 12262: In Haiphong (Vietnam), we showed that more than 40% of HIV/HCV co-infected patients successfully treated with antiretroviral treatment presented liver fibrosis and needed urgently an unavailable treatment for chronic hepatitis C (Nguyen Truong Tam et al., PLOS ONE, 2016).